MGNX

MKT CAP:$204M

MacroGenics, Inc.

Market Cap

$204M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$3.18+$1.57 (+97.52%)

Apr 23, 2026

Company Details

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (...

CEO

Eric Blasius Risser

IPO Date

Oct 10, 2013

Website

www.macrogenics.com

Key Metrics TTM

Revenue

$150M

+0.8% YoY

Net Income

-$75M

EPS (Diluted)

-$1.17

Free Cash Flow

-$83M

Revenue / Share

$2.37

Gross Margin

71.1%

Operating Margin

-48.7%

Net Margin

-49.9%

FCF Margin

-55.5%

P/S

1.4x

P/E

—

Earnings Reports

Q1 2026

May 12, 2026

PENDING

FY 2025

Mar 9, 2026

$150M+0.8%EPS -$1.18

Q4 2025

Mar 9, 2026

$41M+132.5%EPS -$0.22

Q3 2025

Nov 12, 2025

$73M-34.2%EPS $0.27

Q2 2025

Aug 14, 2025

$22M+106.0%EPS -$0.57

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$11M	$11M	-$67M
Q2 22	$26M	$24M	-$42M
Q3 22	$42M	$39M	-$25M
Q4 22	$73M	$26M	$12M
Q1 23	$24M	$21M	-$38M
Q2 23	$13M	$12M	-$45M
Q3 23	$10M	$10M	-$36M
Q4 23	$11M	-$37M	-$49M
Q1 24	$9M	$7M	-$54M
Q2 24	$11M	$8M	-$58M
Q3 24	$111M	$68M	$54M
Q4 24	$18M	$12M	-$53M
Q1 25	$13M	$8M	-$43M
Q2 25	$22M	$13M	-$37M
Q3 25	$73M	$59M	$19M
Q4 25	$41M	$26M	-$12M

Valuation

Quarter	P/S	P/E
Q1 22	7.3x	—
Q2 22	3.0x	—
Q3 22	2.3x	—
Q4 22	2.3x	—
Q1 23	2.8x	—
Q2 23	2.2x	44.8x
Q3 23	2.3x	5.6x
Q4 23	11.1x	—
Q1 24	20.3x	—
Q2 24	6.6x	—
Q3 24	1.5x	—
Q4 24	1.4x	—
Q1 25	0.5x	—
Q2 25	0.5x	—
Q3 25	0.9x	—
Q4 25	0.7x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$58M	-$59M
Q2 22	-$49M	-$50M
Q3 22	-$9M	-$10M
Q4 22	$29M	$29M
Q1 23	-$13M	-$13M
Q2 23	-$2M	-$2M
Q3 23	-$35M	-$36M
Q4 23	-$28M	-$29M
Q1 24	-$46M	-$47M
Q2 24	-$44M	-$46M
Q3 24	$60M	$60M
Q4 24	-$38M	-$39M
Q1 25	-$47M	-$47M
Q2 25	-$47M	-$48M
Q3 25	-$30M	-$31M
Q4 25	$43M	$43M

Capital Expenditures

Quarter	CapEx
Q1 22	$1M
Q2 22	$1M
Q3 22	$804.0K
Q4 22	$393.0K
Q1 23	$359.0K
Q2 23	$286.0K
Q3 23	$499.0K
Q4 23	$620.0K
Q1 24	$1M
Q2 24	$1M
Q3 24	$592.0K
Q4 24	$620.0K
Q1 25	$529.0K
Q2 25	$715.0K
Q3 25	$426.0K
Q4 25	$244.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	-36.8%	+13.4%
Q2 22	-15.4%	-4.5%
Q3 22	+166.5%	-2.9%
Q4 22	+416.7%	-15.6%
Q1 23	+129.5%	-18.6%
Q2 23	-49.5%	-14.3%
Q3 23	-75.1%	-31.2%
Q4 23	-85.3%	-1.7%
Q1 24	-62.8%	-0.1%
Q2 24	-17.8%	+18.7%
Q3 24	+964.8%	+23.1%
Q4 24	+65.4%	+17.5%
Q1 25	+44.9%	-11.2%
Q2 25	+106.0%	-14.5%
Q3 25	-34.2%	-4.1%
Q4 25	+132.5%	-24.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$5M	49.4%
Q2 22	$5M	20.4%
Q3 22	$5M	12.3%
Q4 22	$5M	6.5%
Q1 23	$5M	19.7%
Q2 23	$4M	33.4%
Q3 23	$0	0.0%
Q4 23	$0	0.0%
Q1 24	$6M	61.0%
Q2 24	$7M	61.6%
Q3 24	$6M	5.4%
Q4 24	$11M	63.5%
Q1 25	$4M	33.2%
Q2 25	$4M	16.6%
Q3 25	$4M	4.9%
Q4 25	$3M	6.5%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 22	$61M	$16M
Q2 22	$52M	$14M
Q3 22	$48M	$15M
Q4 22	$46M	—
Q1 23	$46M	$14M
Q2 23	$43M	$14M
Q3 23	$30M	$12M
Q4 23	$47M	—
Q1 24	$46M	$15M
Q2 24	$52M	$14M
Q3 24	$41M	—
Q4 24	$39M	$28M
Q1 25	$40M	$11M
Q2 25	$41M	$9M
Q3 25	$33M	$10M
Q4 25	$34M	$9M

Revenue Segments

Quarter	Product	Revenue From Collaborative Agreements Member	Revenue From Government Agreements Member	Contract Manufacturing	Revenue From Collaborative Agreements	Revenue From Government Agreements	Government Contract
Q1 22	$4M	$7M	$428.0K	—	—	—	—
Q2 22	$5M	$17M	$480.0K	$4M	—	—	—
Q3 22	$4M	$36M	$547.0K	$1M	—	—	—
Q4 22	$4M	—	—	$9M	$60M	$468.0K	—
Q1 23	$3M	$17M	$283.0K	$4M	—	—	—
Q2 23	$5M	$6M	$466.0K	$2M	—	—	—
Q3 23	$5M	$885.0K	$345.0K	$4M	—	—	—
Q1 24	$5M	$1M	$358.0K	$2M	—	—	—
Q2 24	$5M	$2M	$493.0K	$3M	—	—	—
Q3 24	$4M	$101M	—	$5M	—	—	$566.0K
Q1 25	—	$7M	—	$6M	—	—	—
Q2 25	—	$7M	—	$15M	—	—	—
Q3 25	—	$53M	—	$20M	—	—	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$47M	$137M	$184M
Q2 22	$21M	$112M	$134M
Q3 22	$84M	$40M	$124M
Q4 22	$109M	$45M	$154M
Q1 23	$224M	$17M	$242M
Q2 23	$109M	$132M	$240M
Q3 23	$90M	$167M	$256M
Q4 23	$101M	$129M	$230M
Q1 24	$80M	$104M	$184M
Q2 24	$84M	$56M	$140M
Q3 24	$180M	$21M	$200M
Q4 24	$183M	$19M	$202M
Q1 25	$146M	$9M	$154M
Q2 25	$131M	$46M	$176M
Q3 25	$80M	$66M	$146M
Q4 25	$57M	$133M	$190M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	61M	+0.3%	+7.2%
Q2 22	61M	+0.1%	+2.2%
Q3 22	61M	+0.1%	+0.5%
Q4 22	61M	-0.0%	+0.4%
Q1 23	62M	+0.6%	+0.8%
Q2 23	62M	+0.7%	+1.4%
Q3 23	62M	-0.0%	+1.3%
Q4 23	62M	-0.3%	+1.0%
Q1 24	62M	+0.4%	+0.8%
Q2 24	63M	+0.6%	+0.6%
Q3 24	63M	+0.3%	+1.0%
Q4 24	63M	-0.4%	+0.9%
Q1 25	63M	+0.5%	+1.1%
Q2 25	63M	+0.3%	+0.8%
Q3 25	63M	+0.2%	+0.7%
Q4 25	63M	-0.2%	+0.9%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$25.0K	427
Q2 22	$60.9K	427
Q3 22	$97.7K	427
Q4 22	$204.8K	357
Q1 23	$68.6K	357
Q2 23	$36.8K	357
Q3 23	$29.1K	357
Q4 23	$31.6K	339
Q1 24	$26.9K	339
Q2 24	$31.8K	339
Q3 24	$326.6K	339
Q4 24	$52.0K	341
Q1 25	$38.7K	341
Q2 25	$65.2K	341
Q3 25	$213.6K	341
Q4 25	$140.7K	293

Revenue / Employee